FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Merck Sharp x26 Dohme Corp
Merck Sharp x26 Dohme Corporation
Merck Sharp x26 Dohme Corp And Northwestern University
Merck Sharp x26 Dohme Corp_20131212
Merck Sharp x26 Dohme Corp Institute De Recherche Pierre Fabre

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Merck Sharp & Dohme Corp patents


      
Recent patent applications related to Merck Sharp & Dohme Corp. Merck Sharp & Dohme Corp is listed as an Agent/Assignee. Note: Merck Sharp & Dohme Corp may have other listings under different names/spellings. We're not affiliated with Merck Sharp & Dohme Corp, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merck Sharp & Dohme Corp-related inventors


Search recent Press Releases: Merck Sharp & Dohme Corp-related press releases
Count Application # Date Merck Sharp & Dohme Corp patents (updated weekly) - BOOKMARK this page
12015008650503/26/15 new patent  Mono- and di-peg il-10 production; and uses
22015001159001/08/15Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
32012025303210/04/12Novel cationic lipids with short lipid chains for oligonucleotide delivery
42012020281908/09/12Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
52015008390603/26/15 new patent  Biomarkers for monitoring intervention therapies for diabetes
62015008764103/26/15 new patent  Heterocyclic cgrp receptor antagonists
72015008783203/26/15 new patent  Process for making beta 3 agonists and intermediates
82015007899603/19/15Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
92015007903103/19/15Use of pegylated il-10 to treat cancer
102015008059803/19/15Asymmetric synthesis for preparing fluoroleucine alkyl esters
112015006419203/05/15Mammalian cell surface antigens; related reagents
122015005619102/26/15Igf1 biomarker for igf1r inhibitor therapy
132015005122702/19/15Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
142015005124802/19/15Imidazolyl methyl piperidine t-type calcium channel antagonists
152015004425002/12/15Vaccines against clostridium difficile comprising recombinant toxins
162015004534602/12/15Selective glycosidase inhibitors and uses thereof
172015004557502/12/15Process for preparing fluoroleucine alkyl esters
182015003849002/05/15Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
192015003849802/05/15Thrombin inhibitors
202015003850202/05/15Isoxazolopyridine orexin receptor antagonists
212015003870702/05/15Process for making cgrp receptor antagonists
222015003171301/29/15Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
232015003171601/29/15Piperidinone carboxamide azaindane cgrp receptor antagonists
242015003189101/29/15Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts
252015002080601/22/15Dry powder inhaler for delivering multipe agglomerate formulations
262015002395201/22/15Anti-addl monoclonal antibody and uses thereof
272015002407101/22/15Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
282015002504601/22/15Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists
292015001768601/15/15Methods for reducing mannosyltransferase activity in lower eukaryotes
302015001839901/15/15Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
312015001056401/08/15Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
322015000460801/01/15Monocyte-derived nucleic acids and related compositions and methods
332015000533001/01/15Piperidinone carboxamide azaindane cgrp receptor antagonists
342014037726012/25/14Protective vaccine based on staphylococcus aureus sa2074 protein
352014037849312/25/14Fused bicyclic oxazolidinone cetp inhibitor
362014037002512/18/14Uses of mammalian cytokines and agonists; related reagents
372014037113812/18/14Inhibitors of hepatitis c virus replication
382014034997211/27/14Substituted pyrimidines
392014034884111/27/14Anti-gitr antibodies
402014034999811/27/14Pyrrolopyrimidines as janus kinase inhiitors
412014035000211/27/14Imidazopyridin-2-one derivatives
422014034307111/20/14Compositions and methods for treating cancer
432014033619611/13/14Phosphoric acid salts of sitagliptin
442014032927611/06/14Methods for increasing n-glycan occupancy and reducing production of hybrid n-glycans in pichia pastoris strains lacking alg3 expression
452014032351910/30/14Heterocyclic compounds as b-raf inhibitors for treatment of cancer
462014029620210/02/14Substituted piperidinyl compounds useful as gpr119 agonists
472014029622110/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
482014029622210/02/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
492014027501709/18/14Cgrp receptor antagonists
502014025681809/11/14Nano-suspension process
512014024428908/28/14Cold storage system for storing pharmaceutical product containers
522014023429608/21/14Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
532014023430108/21/14Modulation of pilr to treat immune disorders
542014023553708/21/14N-glycosylated insulin analogues
552014022562708/14/14Device for calibrating and verifying the integrity of resistivity-based sensing probes
562014022722308/14/14Pegylated interleukin-10
572014022725008/14/14Stable formulations of antibodies to tslp
582014022729008/14/14Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
592014022729208/14/14Anti-mcam antibodies and associated methods of use
602014022002708/07/141d05 pcsk9 antagonists
612014022138308/07/14Cetp inhibitors
622014021241207/31/14Use of il-33 antagonists to treat fibrotic disease
632014020656307/24/14Biomarkers for psoriasis
642014020664007/24/142'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
652014020664107/24/14Remedy
662014020666507/24/14Selective glycosidase inhibitors and uses thereof
672014020667507/24/14Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
682014020671507/24/14Preparation and use of compounds as protease inhibitors
692014020018007/17/14Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
702014020021307/17/142-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
712014017015406/19/14Engineered anti-il-23r antibodies
722014017065806/19/14Mammalian cytokines; related reagents
732014017143706/19/14Oxazole derivatives useful as inhibitors of faah
742014017145606/19/14Fused tricyclic compounds as mtor inhibitors
752014017148006/19/14Crystalline polymorphic forms of an antidiabetic compound
762014016177006/12/142'-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases
772014016179806/12/14Anti-pcsk9 and methods for treating lipid and cholesterol disorders
782014014744205/29/14Use of il-23 antagonists for treatment of infection
792014014746105/29/14Polypeptides for inducing a protective immune response against staphylococcus aureus
802014014095405/22/14Methods of modulating cytokine activity; related reagents
812014014101205/22/14Engineered anti-tslp antibody
822014014144405/22/14Isolated mammalian monocyte cell genes; related reagents
832014014144505/22/14Isolated mammalian monocyte cell genes; related reagents
842014014211505/22/14Inhibitors of the renal outer medullary potassium channel
852014012836105/08/14Cyclic amide bace-1 inhibitors having a benzamide substituent
862014012836705/08/14Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
872014012836805/08/14Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
882014012003705/01/14Method for detection of amyloids beta oligomers in a fluid sample and uses thereof
892014011291904/24/14Interleukin-10 antibodies
902014011392004/24/14Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
912014010588704/17/14Methods for modulating il-33 activity
922014010641304/17/14Immobilized transaminases and process for making and using immobilized transaminase
932014010734604/17/14Process for preparing chiral dipeptidyl peptidase-iv inhibitors
942014009356404/03/14Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
952014009387504/03/14Mammalian cytokines; receptors; related reagents and methods
962014008804803/27/14Diazeniumdiolate cyclohexyl derivatives
972014008088403/20/14Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
982014005789302/27/14Substituted cycloproply compounds, compositions containing such compounds and methods of treatment
992014005174002/20/14Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1002014004574602/13/14Antidiabetic tricyclic compounds
1012014004582902/13/14Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
1022014004583202/13/14Insulin-like growth factor-1 receptor inhibitors
1032014003762702/06/14Modulation of pilr receptors to treat microbial infections
1042014003894202/06/14Rorgammat inhibitors
1052014003897002/06/14Bridged and fused antidiabetic compounds
1062014003025501/30/14Methods of predicting cancer cell response to therapeutic agents
1072014003076001/30/14Pavec
1082014003125101/30/14Methods of classifying human subjects with regard to cancer prognosis
1092014003134901/30/14Inhibitors of the renal outer medullary potassium channel
1102014002366701/23/14Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
1112014000518201/02/14Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1122013034451212/26/13Cd16a reporter assay for evaluation of adcc potential of biologics
1132013033137212/12/13Cyclic amine substituted oxazolidinone cetp inhibitor
1142013032323912/05/13Modulation of pilr receptors to treat sepsis
1152013032324612/05/13Use of mdl-1 antagonists to treat spondylarthropathy
1162013032325112/05/13Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
1172013032448312/05/13Mammalian cell surface antigens; related reagents
1182013032461012/05/13Cathepsin cysteine protease inhibitors
1192013032472812/05/13Process for the preparation of an orexin receptor antagonist
1202013031635411/28/13Mammalian cytokine; related reagents
1212013029627811/07/13Diazeniumdiolate derivatives
1222013028776310/31/13Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
1232013028021410/24/13Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
1242013028147410/24/13Fused tricyclic inhibitors of mammalian target of rapamycin
1252013026114010/03/13Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
1262013025167709/26/13Genetic markers associated with interferon-alpha response
1272013024369209/19/13Fdg-pet evaluation of ewing's sarcoma sensitivity
1282013023751809/12/13Novel compounds that are erk inhibitors
1292013023085509/05/13Monocyte-derived nucleic acids and related compositions and methods
1302013022558208/29/13Biaryl-spiroaminooxzaoline analogues as alpha 2c adrenergic receptor modulators
1312013022583608/29/13Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
1322013021657508/22/13Recombinant subunit dengue virus vaccine
1332013021769508/22/13Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
1342013021775608/22/13Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
1352013021776608/22/13Formulations for cathepsin k inhibitors
1362013020306008/08/13Mammalian genes; related reagents
1372013018927807/25/13Antagonists of pcsk9
1382013015794006/20/13Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
1392013015672906/20/13Mammalian receptor proteins; related reagents and methods
1402013015677106/20/13Fdf03 antibodies and uses thereof
1412013015036206/13/13Novel pyrazolo[1,5-a]pyrimidine derivatives as mtor inhibitors
1422013014385906/06/13Novel prolylcarboxypeptidase inhibitors
1432013013104105/23/13Spirocyclic compounds
1442013013104205/23/13Spiroxazolidinone compounds
1452013012200905/16/13Engineered anti-il-23p19 antibodies
1462013012320005/16/13Mammalian cell surface antigens; related reagents
1472013012323705/16/13Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
1482013011522305/09/13Antagonists of pcsk9
1492013011623105/09/13Tyrosine kinase inhibitors
1502013010973905/02/13Compositions and methods for short interfering nucleic acid inhibition of nav1.8
1512013009605304/18/13Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
1522013007139003/21/13Method for preparing antibodies having improved properties
1532013006481703/14/13Engineered anti-il-23r antibodies
1542013005985003/07/13Aza-indole derivatives useful as modulators of faah
1552013005335202/28/13Diazeniumdiolate cyclopentyl derivatives
1562013004591402/21/13Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
1572013004092902/14/13Novel prolylcarboxypeptidase inhibitors
1582013004093202/14/13Substituted aryl sulfone derivatives as calcium channel blockers
1592013003456102/07/13Isolated mammalian monocyte cell genes; related reagents
1602013003531202/07/13Cathepsin cysteine protease inhibiors
1612013002351501/24/13Novel spiropiperidine prolylcarboxypeptidase inhibitors
1622013001804801/17/13Oxazole derivatives useful as modulators of faah
1632013001252601/10/13Oxazole derivatives useful as modulators of faah
1642013000579701/03/13Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
1652013000451801/03/13Cyclic amine bace-1 inhibitors having a benzamide substituent
1662012032967912/27/12Eukaryotic cell display systems
1672012031532112/13/12Immunological methods and compositions for the treatment of alzheimer's disease
1682012031620012/13/12Pyridone derivatives
1692012027724011/01/12Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
1702012026477710/18/12Oxadiazole beta carboline derivatives as antidiabetic compounds
1712012023200709/13/12Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens
1722012023208609/13/12Fused tricyclic compounds with adenosine a2a receptor antagonist activity
1732012022588609/06/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1742012021484608/23/12Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1752012021484708/23/122-[1-phenyl-5-hydroxy-4a-substituted-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands
1762012020188508/09/12Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
1772012019690108/02/12Tertiary amide orexin receptor antagonists
1782012019070107/26/12Renin inhibitors
1792012017868107/12/12Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment
1802012017875007/12/12Niacin receptor agonists, compositions containing such compounds and methods of treatment
1812012017239707/05/12Hexahydrocyclopenta[f]indazole 5-yl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
1822012016415806/28/12Anti-addl monoclonal antibody and use thereof
1832012015743806/21/12Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
1842012015743206/21/12Novel pyrrolidine derived beta 3 adrenergic receptor agonists
1852012014277006/07/12Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
1862012014269406/07/12Substituted 4-hydroxypyrimidine-5-carboxamides
1872012014275206/07/12Hiv protease inhibitors
1882012013601205/31/12Amino tetrahydro-pyridopyrimidine pde10 inhibitors
1892012012162405/17/12Hepatitis c virus ns3 protease inhibitors
1902012011913005/17/12Diaphragm valve with improved sealing performance and leak detection
1912012012150805/17/12Radiolabeled cgrp antagonists
1922012012158005/17/12Methods for producing high concentration lyophilized pharmaceutical formulations
1932012012289905/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1942012012290005/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1952012012291105/17/12Piperidinone carboxamide azaindane cgrp receptor antagonists
1962012011589405/10/12Imidazole derivatives useful as modulators of faah and as faah imaging agents
1972012011592105/10/12Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
1982012010860005/03/12Substituted 4-hydroxypyrimidine-5-carboxamides
1992012009500104/19/12Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones
2002012009505504/19/12Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
2012012008348304/05/12Inhibitors of hepatitis c virus replication
2022012008267904/05/12Antagonists of pcsk9
2032012008268004/05/12Antagonists of pcsk9
2042012007679903/29/12Antagonists of pcsk9
2052012007796403/29/12Antagonists of pcsk9
2062012005318103/01/12Pyrrolidine-derived beta 3 adrenergic receptor agonists
2072012004097802/16/12Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
2082012003460802/09/12Microrna as a biomarker of pancreatic islet beta-cell engagement
2092012003521402/09/12Renin inhibitors
2102012003524702/09/12Rna interference mediated inhibition of signal transducer and activator of transcription 6 (stat6) gene expression using short interfering nucleic acid (sina)
2112012002894002/02/12Functionally selective azanitrile alpha-2c adrenoreceptor agonists
2122012002905402/02/12Rna interference mediated inhibition of gata binding protein 3 (gata3) gene expression using short intefering nucleic acid (sina)
2132012002214301/26/12Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina)
2142012002107401/26/12P2x3, receptor antagonists for treatment of pain
2152012002194801/26/12Surface display of whole antibodies in eukaryotes
2162012002214201/26/12Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina)
2172012001601001/19/12Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina)
2182012001601101/19/12Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina)
2192012000958001/12/12Methods for quantitating small rna molecules
2202012001019301/12/12Cgrp receptor antagonists
2212012001027201/12/12Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina)
2222012000428101/05/12Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina)
2232012000428201/05/12Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina)
2242012000428001/05/12Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina)
2252011031291112/22/11Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
2262011030107912/08/11Neuromedin u receptor agonists and uses thereof
2272011029469612/01/11Methods for characterizing agonists and partial agonists of target molecules
2282011029473512/01/11Mechanism of neuromedin u action and uses thereof
2292011029477712/01/11Beta-lactamase inhibitors
2302011026353310/27/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2312011025059110/13/11Method of designing sirnas for gene silencing
2322011025120710/13/11Biaryl-spiroaminooxazoline analogues as alpha 2c adrenergic receptor modulators
2332011024051110/06/11Packaging for oxygen-sensitive pharmaceutical products
2342011023763409/29/11Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
2352011022950809/22/11Polypeptides for inducing a protective immune response against staphylococcus aureus
2362011023049809/22/11Biaryl carboxamides
2372011023052609/22/11Thiazolyl mglur5 antagonists and methods for their use
2382011022419309/15/11Inhibitors of diacylglycerol acyltransferase
2392011022413409/15/11Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
2402011022419509/15/11Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
2412011021817409/08/11Novel cyclic benzimidazole derivatives useful as anti-diabetic agents
2422011021820209/08/11Soluble guanylate cyclase activators
2432011020773708/25/11Substituted bicyclic amines for the treatment of diabetes
2442011020794208/25/11Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]-oxepino[4,5-c]pyrrole
2452011020162108/18/11Angiotensin ii receptor antagonists
2462011019595708/11/11Substituted diazepan orexin receptor antagonists
2472011019030808/04/11Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
2482011019034608/04/11Diphenyl substituted alkanes as flap inhibitors
2492011017805907/21/111,3-oxazolidin -2-one derivatives useful as cetp inhibitors



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merck Sharp & Dohme Corp in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merck Sharp & Dohme Corp with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE